U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H38O6
Molecular Weight 422.5549
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOVASTATIN ACID

SMILES

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC

InChI

InChIKey=QLJODMDSTUBWDW-BXMDZJJMSA-N
InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://clinicaltrials.gov/show/NCT00580970 | http://medical-dictionary.thefreedictionary.com/lovastatin

Lovastatin acid is an active metabolite of hypolipidemic drug Lovastatin. Lovastatin acid inhibits HMG-CoA reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C). Lovastatin in approved for prevention of cardiovascular events and hypercholesterolemia. Off-label use of lovastatin includes treatmetn of diabetic dyslipidemia, familial dysbetalipoproteinemia, familial combined hyperlipidemia, or nephrotic hyperlipidemia. Lovastatin was tested in clinical trials agains radioation injury during therapy of prostate cancer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.64 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

2002
Palliative
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

2002
Preventing
MEVACOR

Approved Use

After oral ingestion, lovastatin, which is an inactive lactone, is hydrolyzed to the lovastatin acid. This is a principal metabolite and an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C).

Launch Date

1987
Primary
MEVACOR

Approved Use

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. MEVACOR is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.

Launch Date

1987
Secondary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.6 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.9 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
76.9 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
83 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Disc. AE: Aspartate aminotransferase increased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Aspartate aminotransferase increased (grade 2-4, 1.3%)
Alanine aminotransferase increased (grade 2-4, 1.3%)
Gastrointestinal disturbance (0.4%)
Rash (0.27%)
Myalgia (0.13%)
Myopathy (0.27%)
Arthralgia (0.13%)
Insomnia (0.13%)
Weight gain (0.13%)
Sources: Page: p.1082, 1083
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 33.3%)
Aspartate aminotransferase increased (grade 2-3, 33.3%)
Alanine aminotransferase increased (grade 2-3, 33.3%)
Sources: Page: p.527
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 28.6%)
Aspartate aminotransferase increased (grade 3, 14.3%)
Alanine aminotransferase increased (grade 3, 14.3%)
Sources: Page: p.527
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Insomnia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myalgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Weight gain 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myopathy 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Rash 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Gastrointestinal disturbance 0.4%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Aspartate aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Aspartate aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Alanine aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Aspartate aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 28.6%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
PubMed

PubMed

TitleDatePubMed
Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma.
2001
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.
2001
An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents.
2001 Apr
The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor.
2001 Apr
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.
2001 Apr
A new simvastatin (mevinolin)-resistance marker from Haloarcula hispanica and a new Haloferax volcanii strain cured of plasmid pHV2.
2001 Apr
Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro.
2001 Apr
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
2001 Apr
Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress.
2001 Apr 1
Statins are magic when you gotta have heart.
2001 Apr 16
Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans.
2001 Apr 16
Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice.
2001 Apr 17
Analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors using liquid chromatography-electrospray mass spectrometry.
2001 Apr 25
Deterioration of the protein kinase C-K(ATP) channel pathway in regulation of coronary flow in hypercholesterolaemic rabbits.
2001 Apr 27
The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to 'interaction of cytosine arabinoside and lovastatin in human leukemia cells'.
2001 Aug
Interaction of cytosine arabinoside and lovastatin in human leukemia cells.
2001 Aug
[Practical questions for the expert].
2001 Feb
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
2001 Jun
Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection.
2001 Jun
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.
2001 Jun
Use of statins and the subsequent development of deep vein thrombosis.
2001 Jun 11
Compactin enhances osteogenesis in murine embryonic stem cells.
2001 Jun 8
Recent advances in the biosynthetic studies of lovastatin.
2001 Mar
[Statins do not prevent restenosis after coronary angioplasty: where to go from here?].
2001 Mar
[AFCAPS/TexCAPS [The Air Force/Texas Coronary Atherosclerosis Prevention Study]].
2001 Mar
Lovastatin blocks basic fibroblast growth factor-induced mitogen-activated protein kinase signaling in coronary smooth muscle cells via phosphatase inhibition.
2001 Mar
[Effect of cholesterol deficiency on the membrane fluidity of Jurkat T lymphocytes].
2001 Mar
Is a statin a statin?
2001 Mar
Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells.
2001 Mar
HMG-CoA reductase inhibitors and P-glycoprotein modulation.
2001 Mar
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.
2001 Mar 1
High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol.
2001 Mar 15
Liver regeneration after hepatectomy.
2001 Mar-Apr
New OTC drugs and devices 2000: a selective review.
2001 Mar-Apr
The National Service Framework on coronary heart disease: is it sufficiently evidence-based?
2001 May
Statin induced myopathy does not show up in MIBI scintigraphy.
2001 May
Revised indications for statin therapies.
2001 May
What do the statin trials tell us?
2001 May
Statins--similarities and differences.
2001 May
Should all patients with cardiovascular disease receive statin therapy?
2001 May
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
2001 May
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.
2001 May
The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens.
2001 May
Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins?
2001 May
Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury.
2001 May
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.
2001 May 1
RhoA is activated during respiratory syncytial virus infection.
2001 May 10
Regulation of sterol regulatory element-binding proteins in hamster intestine by changes in cholesterol flux.
2001 May 18
Lovastatin controls signal transduction in vascular smooth muscle cells by modulating phosphorylation levels of mevalonate-independent pathways.
2001 May-Jun
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
2001 Spring
Patents

Sample Use Guides

Hyperlipidemia and Mixed Dyslipidemia: (Fredrickson Types IIa and IIb). The recommended dosing range is 20-60 mg/day, in single doses taken in the evening at bedtime.
Route of Administration: Oral
Flow cytometry revealed significant increases in three of four lung cancer cell lines in apoptosis and necrosis after lovastatin treatment at 10 uM for 72 h. Lovastatin adversely affected lung cancer cell survival with increases in cell-cycle check-point inhibitors p21WAF and/or p27KIP and a decrease in cyclin D1. All four lung cancer cell lines had a decrease in glutathione after lovastatin treatment consistent with reduced protection against reactive oxidant species. Three of four lung cancer cell lines had increased cytochrome c release with reduced pro-caspase-3 and increases in activated caspase-3. Lovastatin induces apoptosis and necrosis in lung cancer cell lines by causing alterations in the cell cycle, reducing glutathione, and activating p53, Bax protein, and caspases while increasing cytochrome c in apoptosis pathways.
Name Type Language
LOVASTATIN ACID
Common Name English
LOVASTATIN IMPURITY B [EP IMPURITY]
Common Name English
MEVINOLINIC ACID
Common Name English
MSD-803 ACID
Code English
(.BETA.R,.DELTA.R,1S,2S,6R,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-.BETA.,.DELTA.-DIHYDROXY-2,6-DIMETHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-1-NAPHTHALENEHEPTANOIC ACID
Systematic Name English
MK-819
Code English
HYDROXYACID LOVASTATIN [EP IMPURITY]
Common Name English
1-NAPHTHALENEHEPTANOIC ACID, 1,2,6,7,8,8A-HEXAHYDRO-.BETA.,.DELTA.-DIHYDROXY-2,6-DIMETHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (.BETA.R,.DELTA.R,1S,2S,6R,8S,8AR)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1655
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
Code System Code Type Description
DRUG BANK
DB03785
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
FDA UNII
5CLV35Y90C
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
CAS
75225-51-3
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
PUBCHEM
64727
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID20873334
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
NCI_THESAURUS
C77442
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
CHEBI
82985
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY